文献速递白血病

急性髓系白血病患者的代谢重编程取决于基因型并具预后价值

The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker.
PubMed 文献 · Blood Adv · 2021-01-01

该研究采用基于质子高分辨魔角旋转核磁共振的非靶向代谢组学方法,分析54例初诊急性髓系白血病患者的骨髓样本,发现代谢谱随细胞形态学亚型和分子状态呈现高度异质性。2-羟基戊二酸(2-HG)与异柠檬酸脱氢酶突变直接相关且为良好预后标志物,磷脂代谢紊乱(磷酸胆碱和磷酸乙醇胺)则提示预后不良。谷胱甘肽和丙氨酸在化疗耐药患者中过表达。

要点

  • AML患者代谢谱因细胞遗传学亚型和分子状态而异,2-HG与IDH突变直接关联。
  • 2-HG在本队列中为良好预后标志物,磷酸胆碱和磷酸乙醇胺提示预后不良。
  • 谷胱甘肽和丙氨酸在化疗耐药患者中过表达,或反映耐药机制。

核心结论

  • 不同代谢通路依白血病细胞表型和成熟度被激活,代谢重编程显著影响AML预后。

研究设计与样本

  • 研究纳入54例初诊AML患者,采用基于质子高分辨魔角旋转核磁共振的非靶向代谢组学分析骨髓样本,并结合多变量统计分析。

主要发现

  • AML患者代谢谱呈现高度多样性,与不同细胞形态学亚型和分子状态相对应。
  • 2-HG的胞内产生与异柠檬酸脱氢酶突变直接相关,并在本队列中表现为良好预后标志物。
  • 磷脂代谢紊乱通过磷酸胆碱和磷酸乙醇胺两个主要代谢物对预后产生负面影响,可能为侵袭性标志物。
  • 谷胱甘肽和丙氨酸在化疗耐药患者中过表达。

临床怎么用

  • 基于骨髓代谢组学检测2-HG、磷酸胆碱和磷酸乙醇胺等代谢物,可能辅助AML预后分层和耐药识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leukemic cells display some alterations in metabolic pathways, which play a role in leukemogenesis and in patients' prognosis. To evaluate the characteristics and the impact of this metabolic reprogramming, we explore the bone marrow samples from 54 de novo acute myeloid leukemia (AML) patients, using an untargeted metabolomics approach based on proton high-resolution magic angle spinning-nuclear magnetic resonance. The spectra obtained were subjected to multivariate statistical analysis to find specific metabolome alterations and biomarkers correlated to clinical features. We found that patients display a large diversity of metabolic profiles, according to the different AML cytologic subtypes and molecular statuses. The link between metabolism and molecular status was particularly strong for the oncometabolite 2-hydroxyglutarate (2-HG), whose intracellular production is directly linked to the presence of isocitrate dehydrogenase mutations. Moreover, patients' prognosis was strongly impacted by several metabolites, such as 2-HG that appeared as a good prognostic biomarker in our cohort. Conversely, deregulations in phospholipid metabolism had a negative impact on prognosis through 2 main metabolites (phosphocholine and phosphoethanolamine), which could be potential aggressiveness biomarkers. Finally, we highlighted an overexpression of glutathione and alanine in chemoresistant patients. Overall, our results demonstrate that different metabolic pathways could be activated in leukemic cells according to their phenotype and maturation levels. This confirms that metabolic reprogramming strongly influences prognosis of patients and underscores a particular role of certain metabolites and associated pathways in AML prognosis, suggesting common mechanisms developed by leukemic cells to maintain their aggressiveness even after well-conducted induction chemotherapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lo Presti C, Fauvelle F, Jacob MC, et al. The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker. Blood Adv. 2021. PMID: 33570627. doi:10.1182/bloodadvances.2020002981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。